Marker Therapeutics, Inc.

Category: Press Releases

TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer

…Results Meet Management’s Highest Expectations

SEATTLE–(BUSINESS WIRE)–

TapImmune Inc. (TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes.

Read More

TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress

…SEATTLE–(BUSINESS WIRE)–

TapImmune Inc. (TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.

Dear Shareholders,

Over the past few years TapImmune has developed a strong scientific and clinical position in immunotherapy but has lacked the financial resources to fully leverage it. To address this, we now announce the completion of a corporate restructuring to attract the financial backing of some of the most respected names in life science to aid us in executing our product development plans and to provide fuel for our growth.

Read More

TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress

…SEATTLE, WA / Feb 25, 2014 / ACCESSWIRE / TapImmune Inc. (TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.

Dear Shareholders,
Over the past few years TapImmune has developed a strong scientific and clinical position in immunotherapy but has lacked the financial resources to fully leverage it.

Read More

Tapimmune Announces Development Of Advanced Immunotherapeutic Vaccine Expression And Delivery System

…TapImmune is pleased to announce development of a revolutionary cost effective immunotherapeutic vaccine expression and delivery system.

The novel platform is termed TapImmune’s PolyStart™ technology and has been strategically designed to directly enhance the immune system’s ability to stimulate either or BOTH cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be associated with one, or more importantly, ANY cancer, infectious disease or bio-threat.

Read More

TapImmune Chairman Provides Corporate Update on Development Programs & Collaborations

…It is my pleasure to provide an update to existing and potentially new shareholders on the progress we have made over the past few months.

Highlights from the below detailed update include:

Positive progress at the MAYO clinic on the phase 1 HER2/neu clinical trial with interim results expected in the near term.

Read More

TapImmune Provides Operational Update including Human Data Supporting Use of TAP Based Cancer Vaccine Company Establishes Laboratory Facilities in Vancouver Canada

…ANCOUVER, Canada, 31 July, 2007 – TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, opens new laboratory facilities and provides this update to shareholders.

The opening of the new laboratory facility in Vancouver facilitates the transfer of its technology from The University of British Columbia and signifies the start of the Pre-Clinical process to commercialize its core TAP technologies.

Read More

TapImmune Inc. Announces Availability of New Investor Information

…VANCOUVER, British Columbia, July 17, 2007 (PRIME NEWSWIRE) — TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has launched a new corporate website with links to media features on its technologies.

“I am pleased to have this resource available to our shareholders and other interested parties as it provides a comprehensive look at the company and our technology,” said TapImmune Inc.

Read More

TapImmune Inc. Announces Acquisition of Core TAP Technologies and Intellectual Property from The University of British Columbia

…New Name to Reflect a New Direction and Independent Operation

VANCOUVER, BC – TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has fulfilled its financial obligation to The University of British Columbia for the proposed acquisition of its key Transporter Associated with Antigen Processing (TAP) technology platform and patents.

Read More